These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22517203)

  • 1. Corticosteroid-sparing agents: new treatment options.
    Tomkins-Netzer O; Taylor SR; Lightman S
    Dev Ophthalmol; 2012; 51():47-56. PubMed ID: 22517203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory Therapy in Uveitis.
    Tomkins-Netzer O; Talat L; Ismetova F; Samy A; Lightman S
    Dev Ophthalmol; 2016; 55():265-75. PubMed ID: 26501368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical approach to the use of corticosteroids in patients with uveitis.
    Cunningham ET; Wender JD
    Can J Ophthalmol; 2010 Aug; 45(4):352-8. PubMed ID: 20648092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
    Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic immunosuppressive therapies for uveitis in developing countries.
    Agrawal H; Doan H; Pham B; Khosla A; Babu M; McCluskey P; Nguyen QD; Sangwan V; Reddy S; Sawhney S; Tyagi M
    Indian J Ophthalmol; 2020 Sep; 68(9):1852-1862. PubMed ID: 32823402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapy of uveitis.
    Lee FF; Foster CS
    Expert Opin Pharmacother; 2010 May; 11(7):1135-46. PubMed ID: 20367272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I.
    Lee K; Bajwa A; Freitas-Neto CA; Metzinger JL; Wentworth BA; Foster CS
    Expert Opin Pharmacother; 2014 Oct; 15(15):2141-54. PubMed ID: 25226529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunopharmacotherapy of non-infectious uveitis: where do we stand?
    Agrawal R; Lee C; Phatak S; Pavesio C
    Expert Opin Biol Ther; 2014 Dec; 14(12):1719-22. PubMed ID: 25244075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gold standard of noninfectious uveitis: corticosteroids.
    LeHoang P
    Dev Ophthalmol; 2012; 51():7-28. PubMed ID: 22517201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Side-effects of anti-inflammatory therapy in uveitis.
    Uchiyama E; Papaliodis GN; Lobo AM; Sobrin L
    Semin Ophthalmol; 2014; 29(5-6):456-67. PubMed ID: 25325874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management.
    Foster CS; Kothari S; Anesi SD; Vitale AT; Chu D; Metzinger JL; Cerón O
    Surv Ophthalmol; 2016; 61(1):1-17. PubMed ID: 26164736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The philosophy of treatment of uveitis: past, present and future.
    Kruh J; Foster CS
    Dev Ophthalmol; 2012; 51():1-6. PubMed ID: 22517200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of sirolimus in the treatment of patients with refractory uveitis.
    Shanmuganathan VA; Casely EM; Raj D; Powell RJ; Joseph A; Amoaku WM; Dua HS
    Br J Ophthalmol; 2005 Jun; 89(6):666-9. PubMed ID: 15923497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies.
    Nguyen QD; Merrill PT; Sepah YJ; Ibrahim MA; Banker A; Leonardi A; Chernock M; Mudumba S; Do DV
    Ophthalmology; 2018 Dec; 125(12):1984-1993. PubMed ID: 30060978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapies in development for the management of non-infectious uveitis: A review.
    Hassan M; Karkhur S; Bae JH; Halim MS; Ormaechea MS; Onghanseng N; Nguyen NV; Afridi R; Sepah YJ; Do DV; Nguyen QD
    Clin Exp Ophthalmol; 2019 Apr; 47(3):396-417. PubMed ID: 30938012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing biological disease modifying treatment for paediatric uveitis in the real world.
    Oh LJ; Nguyen CL; Phan K; Wong E; Zagora S; Singh-Grewal D; Chaitow J; Grigg JR; McCluskey P
    Clin Exp Ophthalmol; 2019 Aug; 47(6):741-748. PubMed ID: 30834650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatment options for noninfectious uveitis.
    Gomes Bittencourt M; Sepah YJ; Do DV; Agbedia O; Akhtar A; Liu H; Akhlaq A; Annam R; Ibrahim M; Nguyen QD
    Dev Ophthalmol; 2012; 51():134-61. PubMed ID: 22517211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide for ocular inflammatory diseases.
    Pujari SS; Kempen JH; Newcomb CW; Gangaputra S; Daniel E; Suhler EB; Thorne JE; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Foster CS
    Ophthalmology; 2010 Feb; 117(2):356-65. PubMed ID: 19969366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal therapeutic agents in noninfectious uveitic macular edema.
    Shah KK; Majumder PD; Biswas J
    Indian J Ophthalmol; 2018 Aug; 66(8):1060-1073. PubMed ID: 30038143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate for ocular inflammatory diseases.
    Gangaputra S; Newcomb CW; Liesegang TL; Kaçmaz RO; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE; Foster CS; Kempen JH;
    Ophthalmology; 2009 Nov; 116(11):2188-98.e1. PubMed ID: 19748676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.